XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.3

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):

			Three Months Ended September 30,												Nine Months Ended September 30,
			2025						2024						2025						2024
Total revenue (a)			$	72,839					$	110,708					$	108,273					$	130,609
Cost of product sales			—						168						—						614
Cost of manufacturing services			11,589						1,702						25,894						6,195
Research and development expenses:
Lorigerlimab			7,763						6,268						27,188						26,897
MGC030			7,045						4,000						15,217						8,900
MGC028			3,443						4,280						12,118						20,158
Vobramitamab duocarmazine			3,316						10,514						15,969						32,221
Next-generation T-cell engagers			3,104						1,994						8,894						6,575
MGC026			3,028						3,010						11,942						10,865
MGD024			2,125						2,341						7,032						7,285
Preclinical antibody-drug conjugates (ADCs)			862						1,541						4,718						5,918
Margetuximab			—						2,089						650						8,077
Other programs			2,023						4,506						9,470						11,408
Total research and development expenses			32,709						40,543						113,198						138,304
Selling, general and administrative expenses			9,905						14,104						29,925						43,237
Other segment income (loss), net (b)			(1,814)						2,118						279						6,196
Net income (loss)			$	16,822					$	56,309					$	(60,465)					$	(51,545)

(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.

(b) Other segment income (loss), net includes interest and other income and interest and other expense.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration